openPR Logo
Press release

Chagas Disease Pipeline Assessment Report (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Mitsubishi Tanabe Pharma Corporation, Eisai Co Ltd, Selva Therapeutics, ConserV Bioscience, Seren Pharmaceuticals, 7 Hills Pharma

05-25-2023 05:24 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Chagas Disease Pipeline Assessment Report (2023) Covering

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on developing novel therapies in the Chagas Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanisms of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Chagas Disease Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chagas Disease Therapeutics Market.

The report provides a detailed description of the Chagas Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Chagas Disease Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chagas Disease Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Chagas Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chagas Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Chagas Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Chagas Disease treatment market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Commercial Development Activities in the Chagas Disease Therapeutics Domain:
https://www.delveinsight.com/report-store/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Chagas Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chagas Disease Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Chagas Disease. Currently, Seren Pharmaceuticals is leading the therapeutics market with its Chagas Disease drug candidates in the most advanced stage of clinical development.

Request for Sample PDF to Understand More About the Chagas Disease Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chagas Disease Companies in the Therapeutics Market Include:
• Mitsubishi Tanabe Pharma Corporation
• Eisai Co Ltd
• Selva Therapeutics
• ConserV Bioscience
• Seren Pharmaceuticals
• 7 Hills Pharma
And Many Others

Emerging and Marketed Chagas Disease Therapies Covered in the Report Include:
• Fosravuconazole: Seren Pharmaceuticals: Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma, granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole.

Get an in-depth Assessment of the Emerging Therapies and Chagas Disease Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Chagas Disease Current Treatment Patterns
4. Chagas Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chagas Disease Late-Stage Products (Phase-III)
7. Chagas Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chagas Disease Discontinued Products
13. Chagas Disease Product Profiles
14. Chagas Disease Companies
15. Chagas Disease Drugs
16. Dormant and Discontinued Products
17. Chagas Disease Unmet Needs
18. Chagas Disease Future Perspectives
19. Chagas Disease Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/chagas-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Healthcare Reports by DelveInsight
Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market

Mucinous cystic neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market

Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market

Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market

Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

HDAC Inhibitors Market
https://www.delveinsight.com/report-store/hdac-inhibitors-market

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market

mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market

Asthma Diagnostic Devices Market
https://www.delveinsight.com/report-store/asthma-diagnostic-devices-market

Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Sacral Nerve Stimulator Devices Market
https://www.delveinsight.com/report-store/sacral-nerve-stimulator-devices-market

Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market

Implantable Cardioverter Defibrillators (ICDs) Market
https://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market

India Healthcare Outlook Report
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chagas Disease Pipeline Assessment Report (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Mitsubishi Tanabe Pharma Corporation, Eisai Co Ltd, Selva Therapeutics, ConserV Bioscience, Seren Pharmaceuticals, 7 Hills Pharma here

News-ID: 3067050 • Views: 391

More Releases from DelveInsight Business Research LLP

Corneal Endothelial Dystrophy Pipeline Assessment (2023 Updates) | In-depth Insi …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working to develop novel therapies in the Corneal Endothelial Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Corneal Endothelial Dystrophy Pipeline Insight, 2023"
Congenital Hyperinsulinism Pipeline Assessment (2023 Updates) | In-depth Insight …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working to develop novel therapies in the Congenital Hyperinsulinism therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Congenital Hyperinsulinism Pipeline Insight, 2023" report by
Cryoprin Associated Periodic Syndrome (CAPS) Pipeline Assessment Covering the Cl …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working to develop novel therapies in the Cryoprin Associated Periodic Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Cryoprin Associated Periodic Syndrome (CAPS)
Congenital Adrenal Hyperplasia Pipeline Assessment (2023) Covering Clinical Tria …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Congenital Adrenal Hyperplasia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Congenital Adrenal Hyperplasia Pipeline Insight,

All 5 Releases


More Releases for Chagas

2018 – 2024 Chagas Disease Management Market | Global Industry Report
2018 – 2024 Chagas Disease Management Market | Global Industry Report A Recent Market Study On Chagas Disease And Its Current Trends And Future Insights Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. It is transmitted by kissing bugs or triatomine bugs. It can also be transmitted through blood transfusions, in pregnancy, and organ transplantation. In early stage of the Chagas disease, the symptoms include swollen
Chagas Disease Treatment Market to Surpass US$ 10.29 Mn Threshold by 2025
Chagas disease is a tropical parasitic disease and is endemic in 21 countries in Latin America. Chagas disease can transmitted through blood transfusion, organ transplantation, as well as congenital and oral transmissions. Chagas disease is endemic to Latin America, however, in the recent past, there is a rise in global incidence of Chagas disease due to the migration of Latin American people to other countries. According to data published by
Chagas Disease Treatment Market - Global Industry Insights, and Forecast till 20 …
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,
Chagas Disease Treatment Market - Insights
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,
Chagas Disease Treatment Market - Insights, Analysis, Size, Trends and Forecast, …
American trypanosomiasis also known as Chagas disease is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs. The parasites hide during the day time and become active at night and feed on human blood. T. cruzi can also be transmitted by food contaminated with the parasite, blood transfusion, transmission from infected mother to newborn during gestational period, organ transplant, and laboratory accidents. Its
Chagas Disease (American Trypanosomiasis) Market, Growth, Sales -Pipeline Review …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until 2022. Request For